CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know

CRISPR Therapeutics AG (CRSP) closed at $71.96 in the latest trading session, marking a +0.69% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.57% for the day. At the same time, the Dow added 0.83%, and the tech-heavy Nasdaq gained 0.39%.

Coming into today, shares of the company had lost 13.08% in the past month. In that same time, the Medical sector gained 0.13%, while the S&P 500 gained 2.97%.

The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.64 per share, which would represent a year-over-year decline of 144.78%. In the meantime, our current consensus estimate forecasts the revenue to be $7.03 million, indicating a 92.97% decline compared to the corresponding quarter of the prior year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$6.28 per share and revenue of $101.53 million, indicating changes of -223.71% and -72.65%, respectively, compared to the previous year.

Investors should also pay attention to any latest changes in analyst estimates for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 10.24% lower. CRISPR Therapeutics AG currently has a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 90, this industry ranks in the top 36% of all industries, numbering over 250.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.

4 Oil Stocks with Massive Upsides

Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold." 

Zacks Investment Research has just released an urgent special report to help you bank on this trend. 

In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. 

Download your free report now to see them.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.